Erythrocyte Transfusion
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Vascular Medicine".
Deadline for manuscript submissions: closed (1 March 2022) | Viewed by 20659
Special Issue Editor
Special Issue Information
Dear Colleagues,
Erythrocyte transfusion can be a life-saving intervention e.g. in severe anemic patients to increase oxygen delivery to the tissues; however, it is not without its risks. Over the past decade’s clinicians have become more hesitant to transfuse patients due to insight in potential life-threatening side effects including severe adverse pulmonary transfusion reactions such as transfusion-related acute lung injury and transfusion-associated circulatory overload. Patients on the ward developing pulmonary complications after transfusion are often admitted to intensive care unit (ICU), require mechanical ventilation and have an increased mortality. Especially in critical care transfusion research has flourished and provided more insight in the balance between benefit and harm of erythrocyte transfusion. Next to patients transferred to the ICU due to pulmonary complications after transfusion, patients already admitted to the ICU have also an increased risk for transfusion related morbidity and mortality. At this moment still over 40% of patients in the ICU receive at least one transfusion and their underlying condition increases their susceptibility. Liberal transfusion strategies have not shown benefit and some studies show worse outcomes in these patients. Erythrocyte transfusion in the critical care setting is more and more regarded as a drug which has strict indication criteria with a small therapeutic window and is given as part treatment strategy to achieve a specific goal. Transfusion research is ongoing, investigating specific patient groups that may benefit more from transfusion and identify at-risk patient groups, understanding pathomechanisms for adverse transfusion reactions, improving transfusion safety and improving blood products.
Prof. Dr. Alexander Vlaar
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Erythrocyte transfusion
- Blood cell transfusion
- Anemia treatment
- adverse transfusion reactions
- pulmonary complications
